MiFID medicine may be poison for small firms, warns Nordea AM

The head of Nordea Asset Management says new rules targeting conflicts of interest in his industry are hurting smaller fund managers as they struggle to keep up with the demands.

Nils Bolmstrand Head of Nordea Asset Management is worried about smaller asset managers ability to pay for research after implementation of MIFID II.

Nils Bolmstrand, chief executive officer of Nordea Asset Management -- a unit of Nordea Bank which oversees about USD 257 billion -- says new industry rules may end up being a case of the medicine killing the patient.

Europe’s revised Markets in Financial Instruments Directive (MiFID), which took effect at the beginning of this year, was designed to improve transparency and end conflicts of interest across the financial industry.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Further reading

Latest news

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch